
0:00
1:01:54
Following its recent US FDA approval, on this episode, Pip and Rich discuss mitapivat, an allosteric activator of red-cell pyruvate kinase. They focus on ENERGIZE, a randomised controlled trial of mitapivat vs placebo (2:1) randomisation in people living with transfusion dependent thalassaemia. It met its primary endpoint of achieving significantly more patients reaching a haemoglobin rise of at least 1 g/L. However, Pip and Rich discuss the relevance of this surrogate endpoint as well as the small effects on fatigue and quality of life.
Hosted on Acast. See acast.com/privacy for more information.
Mais episódios de "Don't Just Read the Abstract"



Não percas um episódio de “Don't Just Read the Abstract” e subscrevê-lo na aplicação GetPodcast.








